Annual financial impact of well-differentiated thyroid cancer care in the United States.
about
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent TumorsReview of Factors Related to the Thyroid Cancer Epidemic.Do US thyroid cancer incidence rates increase with socioeconomic status among people with health insurance? An observational study using SEER population-based dataThe thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population.Should small papillary thyroid cancer be observed? A population-based study.Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies.Diagnostic accuracy of thyroid nodule growth to predict malignancy in thyroid nodules with benign cytology: systematic review and meta-analysis.National Trends and Factors Associated with Hospital Costs Following Thyroid Surgery.The Impact of Subclinical Disease and Mechanism of Detection on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Olmsted County, Minnesota During 1935 Through 2012Development of prognostic signatures for intermediate-risk papillary thyroid cancerLenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer.Thyroid Cancer and Nonsteroidal Anti-Inflammatory Drug Use: A Pooled Analysis of Patients Older Than 40 Years of AgeAssociation between screening and the thyroid cancer "epidemic" in South Korea: evidence from a nationwide study.Concomitant thyroid disease and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy.Insights into the management of papillary microcarcinoma of the thyroid.Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Historical Context, Diagnosis, and Future Challenges.The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients.Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology.Association of Insurance Expansion With Surgical Management of Thyroid Cancer.Cost-effectiveness of intraoperative nerve monitoring in avoidance of bilateral recurrent laryngeal nerve injury in patients undergoing total thyroidectomy.Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015).Is postablation whole-body 131 I scintigraphy still necessary in intermediate-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL?A case-control study of exposure to organophosphate flame retardants and risk of thyroid cancer in women.Public health implications of overscreening for carotid artery stenosis, prediabetes, and thyroid cancer.Early prediction of lenvatinib treatment efficacy by using F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational studRoutine thyroglobulin, neck ultrasound and physical examination in the routine follow up of patients with differentiated thyroid cancer-Where is the evidence?
P2860
Q28274899-770657CE-F694-4A50-916D-C946F229773AQ30234328-EAD22563-6109-41AD-902A-D163921B5393Q31030724-559C96AA-DE33-414F-8CE6-730503626DC6Q33648181-15187BB9-0403-4333-8305-4C73CFEF8803Q35202380-D9A6D8BD-17FC-4957-ACB4-22C905D0454AQ35814599-1DE43851-DC69-473B-BC34-2431AC7ECB2FQ35840041-332D484B-0D71-4CE6-887F-672C71E0359BQ35865211-26BA4D08-9EFB-43A6-A002-883F2DE9CF22Q36030255-E7EA6545-3006-4305-9B17-ABA1856166F6Q36134855-D198A9C5-ADEC-4E81-8E39-E258FF715CA0Q36333815-47FB3F2C-2D87-4DFE-8812-D123351523EEQ36385997-C556E375-D1B3-4DAE-82E7-3793950CA3ABQ37459105-B4D407A4-24E5-4188-A0DF-09D5C54DACBFQ38598682-C60526BD-E16F-4F17-9908-7362B1C40E1EQ38669235-BC2559B5-B633-4A59-9498-509A2F353E82Q38677660-7F119A06-4D28-4C07-BE4B-56C66AAA03DBQ38737374-D2BD89C8-BF36-4362-9446-3DFA12980510Q38831911-90E10183-E5D2-4123-B2B4-C29EB2429ADBQ39786729-6D846C58-F767-4642-871A-A1F152ED9BD7Q46635101-9CD7A605-5804-4D35-986D-8BDF1E8926EBQ48721751-BF8C230B-2699-46F7-B445-065F03C6777BQ50067340-63F619E3-3004-4FA9-8DD3-D1A2580FA77FQ53059213-DD181C94-6C4D-45DA-8D2C-F46B7BF4F00AQ55253072-0D014E78-8852-4A04-9857-E580C2011099Q55516978-4DAF6EEC-D6A4-4F7B-AC23-08F103C5915BQ56515680-EF315AA1-8312-4FE2-8F94-00AC4743A698Q58733117-7B778BA2-3521-4F07-98CB-F20243F8063A
P2860
Annual financial impact of well-differentiated thyroid cancer care in the United States.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Annual financial impact of well-differentiated thyroid cancer care in the United States.
@en
Annual financial impact of well-differentiated thyroid cancer care in the United States.
@nl
type
label
Annual financial impact of well-differentiated thyroid cancer care in the United States.
@en
Annual financial impact of well-differentiated thyroid cancer care in the United States.
@nl
prefLabel
Annual financial impact of well-differentiated thyroid cancer care in the United States.
@en
Annual financial impact of well-differentiated thyroid cancer care in the United States.
@nl
P2093
P2860
P356
P1433
P1476
Annual financial impact of well-differentiated thyroid cancer care in the United States.
@en
P2093
Carrie C Lubitz
Chung Y Kong
G Scott Gazelle
Gilbert H Daniels
Konstantinos P Economopoulos
Yufei Chen
P2860
P304
P356
10.1002/CNCR.28562
P407
P577
2014-01-30T00:00:00Z